Fimasartan
CARDIOVASCULAR SYSTEM
Also known as: BR-A-657, fimasartan potassium, fimasartan potassium hydrate, fimasartan potassium trihydrate, kanarb
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Fimasartan is a drug catalogued in DrugCentral. It was first approved by the Korean Food and Drug Administration (KFDA) in 2010. DrugCentral lists 1 molecular target, including AGTR1. Recorded indications include Hypertensive disorder.
- Molecular targets: AGTR1 (1 listed in DrugCentral).
- Indications: Hypertensive disorder.
- ATC code: C09CA10 (Angiotensin II receptor blockers (ARBs), plain).
- Molecular formula: C27H31N7OS; molecular weight 501.65 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Type-1 angiotensin II receptor | AGTR1 | antagonist | IC50 9.38 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2010-09-01 | Korean Food and Drug Administration (KFDA) | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C09CA10 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN › Angiotensin II receptor blockers (ARBs), plain |
C09DA10 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs) and diuretics |
C09DB09 | CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs) and calcium channel blockers |
C10BX16 | CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs |
Chemical structure
| Molecular formula | C27H31N7OS |
|---|---|
| Molecular weight | 501.65 g/mol |
| CAS number | 247257-48-3 |
| InChIKey | AMEROGPZOLAFBN-UHFFFAOYSA-N |
| PubChem CID | 9870652 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Fimasartan used for?
DrugCentral lists the following indications for Fimasartan: Hypertensive disorder.
How does Fimasartan work?
Its molecular targets in DrugCentral include AGTR1 (antagonist).
When was Fimasartan first approved?
Fimasartan was first approved by the Korean Food and Drug Administration (KFDA) in 2010.
What is the chemical formula of Fimasartan?
Fimasartan has the molecular formula C27H31N7OS and a molecular weight of 501.65 g/mol.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4906 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1951143 — compound record and bioactivity
- PubChem CID 9870652 — chemical identifiers
- DrugBank DB09279 — drug record
- FDA UNII P58222188P — substance identity
- UniProt P30556 (AGTR1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.